Incyte Says Data From Phase 2 Study Evaluating MRGPRX4 (INCB000547) In Cholestatic Pruritus Does Not Support Further Development
INCYNovember 18, 2024
Read more →Incyte To Pause Enrollment In Ongoing Phase 2 Study Of MRGPRX2 (INCB000262) In Chronic Spontaneous Urticaria;
INCYNovember 18, 2024
Read more →Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks
INCYNovember 15, 2024
Read more →Cracking The Code: Understanding Analyst Reviews For Incyte
INCYNovember 14, 2024
Read more →RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $80
INCYNovember 14, 2024
Read more →Incyte Acquires 2 Downtown Wilmington Office Buildings, Expanding Its Presence In Delaware; Financial Terms Not Disclosed
INCYMay 21, 2024
Read more →4 Analysts Have This to Say About Incyte
INCYAnalysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter:
May 4, 2022
Read more →RBC Capital Maintains Outperform on Incyte, Lowers Price Target to $88
INCYMay 4, 2022
Read more →SVB Leerink Maintains Underperform on Incyte, Raises Price Target to $58
INCYMay 4, 2022
Read more →Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance
INCYMay 3, 2022
Read more →Incyte: Q1 Earnings Insights
INCYIncyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
May 3, 2022
Read more →Incyte Sees FY22 Jakafi Net Product Revenues $2.33B-$2.40B
INCYMay 3, 2022
Read more →Incyte Q1 Adj. EPS $0.55 Misses $0.68 Estimate, Sales $733.24M Miss $750.66M Estimate
INCYMay 3, 2022
Read more →Incyte, Maruho Announce Strategic Alliance Agreement For Ruxolitinib Cream In Japan
INCYApril 28, 2022
Read more →